Search results
Results From The WOW.Com Content Network
Tuberculosis vaccines. Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch. [1] As of 2021, the only effective tuberculosis vaccine in common use is the Bacillus Calmette-Guérin (BCG) vaccine, first used on humans in 1921. [2][3 ...
D03063. D06466. The Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). [9] It is named after its inventors Albert Calmette and Camille Guérin. [10][11] In countries where tuberculosis or leprosy is common, one dose is recommended in healthy babies as soon after birth as possible. [9]
Tuberculosis (TB), also known colloquially as the " white death ", or historically as consumption, [8] is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. [1] Tuberculosis generally affects the lungs, but it can also affect other parts of the body. [1] Most infections show no symptoms, in which case it is known ...
The history of tuberculosis encompasses the origins of the disease, tuberculosis (TB) through to the vaccines and treatments methods developed to contain and mitigate its impact. Throughout history, the disease tuberculosis has been variously known as consumption, phthisis, and the White Plague. It is generally accepted that the causative agent ...
About Aeras. Aeras is a nonprofit biotech with a social mission, dedicated to advancing the development of new tuberculosis vaccines. In collaboration with global partners in Africa, Asia, North ...
Mycobacterium tuberculosis (M. tb), also known as Koch's bacillus, is a species of pathogenic bacteria in the family Mycobacteriaceae and the causative agent of tuberculosis. [1][2] First discovered in 1882 by Robert Koch, M. tuberculosis has an unusual, waxy coating on its cell surface primarily due to the presence of mycolic acid.
Rigorous preclinical studies in different TB-relevant animal models - mice, guinea pigs and non-human primates - conducted between 2001 and 2011 have shown adequate attenuation, safety and improved immunogenicity and protective efficacy against M. tuberculosis challenge as compared to BCG, thus fulfilling regulatory WHO guidelines and the Geneva consensus requirements for progressing live ...
M72/AS01E is an experimental tuberculosis vaccine. If approved, it would be the first vaccine for tuberculosis in more than a century after the BCG vaccine. [1] [2]It was initially developed by GSK plc and funded by non-profits and governments due to the limited commercial potential of tuberculosis vaccines, which are mainly needed in poor countries.